Cynata Therapeutics Limited Stock Market Value

CYYNF Stock  USD 0.15  0.00  0.00%   
Cynata Therapeutics' market value is the price at which a share of Cynata Therapeutics trades on a public exchange. It measures the collective expectations of Cynata Therapeutics Limited investors about its performance. Cynata Therapeutics is trading at 0.15 as of the 10th of January 2026. This is a No Change since the beginning of the trading day. The stock's lowest day price was 0.15.
With this module, you can estimate the performance of a buy and hold strategy of Cynata Therapeutics Limited and determine expected loss or profit from investing in Cynata Therapeutics over a given investment horizon. Check out Cynata Therapeutics Correlation, Cynata Therapeutics Volatility and Cynata Therapeutics Alpha and Beta module to complement your research on Cynata Therapeutics.
Symbol

Please note, there is a significant difference between Cynata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cynata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cynata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Cynata Therapeutics 'What if' Analysis

In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cynata Therapeutics' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cynata Therapeutics.
0.00
12/11/2025
No Change 0.00  0.0 
In 31 days
01/10/2026
0.00
If you would invest  0.00  in Cynata Therapeutics on December 11, 2025 and sell it all today you would earn a total of 0.00 from holding Cynata Therapeutics Limited or generate 0.0% return on investment in Cynata Therapeutics over 30 days. Cynata Therapeutics is related to or competes with Calliditas Therapeutics, Vicapsys Life, Zivo Bioscience, Biostem Technologies, Relief Therapeutics, Amplia Therapeutics, and Helix BioPharma. Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem ... More

Cynata Therapeutics Upside/Downside Indicators

Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cynata Therapeutics' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cynata Therapeutics Limited upside and downside potential and time the market with a certain degree of confidence.

Cynata Therapeutics Market Risk Indicators

Today, many novice investors tend to focus exclusively on investment returns with little concern for Cynata Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cynata Therapeutics' standard deviation. In reality, there are many statistical measures that can use Cynata Therapeutics historical prices to predict the future Cynata Therapeutics' volatility.
Hype
Prediction
LowEstimatedHigh
0.010.153.30
Details
Intrinsic
Valuation
LowRealHigh
0.010.123.27
Details
Naive
Forecast
LowNextHigh
00.163.31
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.150.150.15
Details

Cynata Therapeutics Backtested Returns

Cynata Therapeutics appears to be out of control, given 3 months investment horizon. Cynata Therapeutics secures Sharpe Ratio (or Efficiency) of 0.13, which signifies that the company had a 0.13 % return per unit of risk over the last 3 months. We have found sixteen technical indicators for Cynata Therapeutics Limited, which you can use to evaluate the volatility of the firm. Please makes use of Cynata Therapeutics' Standard Deviation of 3.08, risk adjusted performance of 0.0991, and Mean Deviation of 0.7461 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Cynata Therapeutics holds a performance score of 10. The firm shows a Beta (market volatility) of -0.89, which signifies possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning Cynata Therapeutics are expected to decrease slowly. On the other hand, during market turmoil, Cynata Therapeutics is expected to outperform it slightly. Please check Cynata Therapeutics' variance and kurtosis , to make a quick decision on whether Cynata Therapeutics' price patterns will revert.

Auto-correlation

    
  0.00  

No correlation between past and present

Cynata Therapeutics Limited has no correlation between past and present. Overlapping area represents the amount of predictability between Cynata Therapeutics time series from 11th of December 2025 to 26th of December 2025 and 26th of December 2025 to 10th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cynata Therapeutics price movement. The serial correlation of 0.0 indicates that just 0.0% of current Cynata Therapeutics price fluctuation can be explain by its past prices.
Correlation Coefficient0.0
Spearman Rank Test1.0
Residual Average0.0
Price Variance0.0

Cynata Therapeutics lagged returns against current returns

Autocorrelation, which is Cynata Therapeutics pink sheet's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Cynata Therapeutics' pink sheet expected returns. We can calculate the autocorrelation of Cynata Therapeutics returns to help us make a trade decision. For example, suppose you find that Cynata Therapeutics has exhibited high autocorrelation historically, and you observe that the pink sheet is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
   Current and Lagged Values   
       Timeline  

Cynata Therapeutics regressed lagged prices vs. current prices

Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Cynata Therapeutics pink sheet is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Cynata Therapeutics pink sheet is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Cynata Therapeutics pink sheet over time.
   Current vs Lagged Prices   
       Timeline  

Cynata Therapeutics Lagged Returns

When evaluating Cynata Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Cynata Therapeutics pink sheet have on its future price. Cynata Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Cynata Therapeutics autocorrelation shows the relationship between Cynata Therapeutics pink sheet current value and its past values and can show if there is a momentum factor associated with investing in Cynata Therapeutics Limited.
   Regressed Prices   
       Timeline  

Currently Active Assets on Macroaxis

Other Information on Investing in Cynata Pink Sheet

Cynata Therapeutics financial ratios help investors to determine whether Cynata Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cynata with respect to the benefits of owning Cynata Therapeutics security.